---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-030297"
form_type: "8-K"
ticker: "AVR"
cik: "0002011514"
company_name: "Anteris Technologies Global Corp."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:55:46.484771+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Anteris Technologies reports Q2 2025 net loss $42.7M; cash $28.4M; 130 DurAVR implants

## Summary
- Revenue from ordinary activities $1.17M for six months, down 16% YoY; net loss $42.7M, up 22% YoY.
- 130 patients implanted with DurAVR THV since start; 21 in Q2 2025; 79 clinical sites qualified for PARADIGM trial.
- R&D expenses $16.3M in Q2 on PARADIGM trial preparation and manufacturing scale-up.
- Cash and equivalents $28.4M at June 30, 2025; net operating cash outflow $41.0M in H1 2025.
- No dividend declared; board appointed two new directors David Roberts and Gregory Moss.

## SEC filing metadata
- accession: 0001140361-25-030297
- form_type: 8-K
- ticker: AVR
- cik: 0002011514
- company_name: Anteris Technologies Global Corp.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2011514/000114036125030297/0001140361-25-030297-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2011514/000114036125030297/ef20053645_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-030297
- JSON: https://secwatch.observer/filing/0001140361-25-030297.json
- Plain text: https://secwatch.observer/filing/0001140361-25-030297.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.